Trial Outcomes & Findings for Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea (NCT NCT05022563)

Last Updated: 2023-08-03

Results Overview

Treatment interruption was defined as when a participant had a gap with no new treatment within 30 days of the estimated end of supply of index treatment, but subsequently restarted the index treatment after this period of 30 days. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.

Recruitment status

COMPLETED

Target enrollment

55759 participants

Primary outcome timeframe

From index date up to treatment interruption, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Results posted on

2023-08-03

Participant Flow

Data of participants diagnosed with venous thromboembolism (VTE) between 1 Mar 2013 and 30 Jun 2019 and received first prescription of anticoagulants within 30 days of VTE diagnosis in real world clinical practice, were retrieved from South Korea's health insurance review and assessment service (HIRA) database. Available data were extracted and evaluated during approximately 1 month of this retrospective observational study.

Study was to be conducted in 2 phases. Phase 1: to describe anticoagulant treatment pattern according to index VTE treatment (PAC only, warfarin based, NOAC based treatment). Phase 2: to compare risk of major bleeding according to specific type of OAC treatment. But, as assessed by real world data review committee Phase 2 was not conducted due to insufficient statistical power that would lead to small and imbalanced sample sizes in comparison groups. Only Phase 1 data were studied and reported.

Participant milestones

Participant milestones
Measure	Warfarin-Based Therapy Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	Non-vitamin K Antagonist Oral Anticoagulants (NOAC)-Based Therapy: Apixaban Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	Parenteral Anticoagulants (PAC) Only Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Overall Study STARTED	11208	5047	2103	2342	26276	8783
Overall Study Without Active Cancer	10390	4543	1894	2078	23049	6550
Overall Study With Active Cancer (Diagnosis of Cancer Within Past 6 Months of Index Date)	818	504	209	264	3227	2233
Overall Study COMPLETED	11208	5047	2103	2342	26276	8783
Overall Study NOT COMPLETED	0	0	0	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Warfarin-Based Therapy n=11208 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=5047 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=2103 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=2342 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=26276 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=8783 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	Total n=55759 Participants Total of all reporting groups
Age, Customized Without Active Cancer · 18-40 years	974 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	269 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	138 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	142 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2042 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	527 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4092 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Age, Customized Without Active Cancer · 40-65 years	2920 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	998 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	481 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	479 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	6456 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1643 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	12977 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Age, Customized Without Active Cancer · >=65 years	6496 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3276 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1275 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1457 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	14551 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4380 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	31435 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Age, Customized With Active Cancer · 18-40 years	7 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	68 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	59 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	144 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Age, Customized With Active Cancer · 40-65 years	232 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	170 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	54 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	91 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1007 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	927 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2481 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Age, Customized With Active Cancer · >=65 years	579 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	332 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	151 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	169 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2152 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1247 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4630 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Sex: Female, Male Without Active Cancer · Female	5978 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2958 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1126 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1288 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	13498 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3671 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	28519 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Sex: Female, Male Without Active Cancer · Male	4412 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1585 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	768 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	790 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	9551 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2879 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	19985 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Sex: Female, Male With Active Cancer · Female	394 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	256 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	101 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	117 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1526 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1095 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3489 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Sex: Female, Male With Active Cancer · Male	424 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	248 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	108 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	147 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1701 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1138 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3766 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Race and Ethnicity Not Collected	—	—	—	—	—	—	0 Participants Race and Ethnicity were not collected from any participant.
Number of Participants According to Type of Index VTE Event Without Active Cancer · DVT only	4232 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2265 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	499 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	689 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	10919 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2822 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	21426 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants According to Type of Index VTE Event Without Active Cancer · PE with/without DVT	6158 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2278 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1395 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1389 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	12130 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3728 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	27078 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants According to Type of Index VTE Event With Active Cancer · DVT only	264 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	164 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	44 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	71 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	918 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	735 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2196 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants According to Type of Index VTE Event With Active Cancer · PE with/without DVT	554 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	340 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	165 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	193 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2309 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1498 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	5059 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Major Orthopedic Surgery-provoked VTE Without Active Cancer	183 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	78 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	53 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	43 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	480 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	119 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	956 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Major Orthopedic Surgery-provoked VTE With Active Cancer	2 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	10 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	6 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	22 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants According to Health Insurance Type Without Active Cancer · National Health Insurance	9418 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4156 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1703 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1889 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	21088 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	5845 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	44099 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants According to Health Insurance Type Without Active Cancer · Medical aid	969 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	387 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	191 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	188 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1953 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	698 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4386 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants According to Health Insurance Type Without Active Cancer · Veterans	3 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	8 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	7 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	19 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants According to Health Insurance Type With Active Cancer · National Health Insurance	748 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	471 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	195 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	240 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3014 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2123 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	6791 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants According to Health Insurance Type With Active Cancer · Medical aid	68 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	33 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	14 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	23 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	213 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	109 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	460 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants According to Health Insurance Type With Active Cancer · Veterans	2 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year Without Active Cancer · 2012	0 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year Without Active Cancer · 2013	3035 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1085 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	804 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4928 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year Without Active Cancer · 2014	2631 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2994 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	955 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	6585 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year Without Active Cancer · 2015	1664 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	224 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	345 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4039 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1012 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	7284 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year Without Active Cancer · 2016	1188 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	837 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	540 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	182 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4160 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1118 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	8025 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year Without Active Cancer · 2017	939 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1144 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	547 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	537 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4215 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1116 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	8498 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year Without Active Cancer · 2018	679 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1496 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	304 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	825 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4438 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1021 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	8763 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year Without Active Cancer · 2019	254 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	840 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	151 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	534 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2118 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	524 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4421 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year With Active Cancer · 2012	0 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year With Active Cancer · 2013	253 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	165 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	244 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	662 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year With Active Cancer · 2014	213 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	441 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	366 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1020 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year With Active Cancer · 2015	131 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	19 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	32 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	503 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	381 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1066 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year With Active Cancer · 2016	79 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	64 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	65 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	14 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	605 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	361 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1188 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year With Active Cancer · 2017	79 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	117 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	66 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	43 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	584 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	355 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1244 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year With Active Cancer · 2018	47 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	174 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	31 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	109 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	631 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	358 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1350 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants Classified According to the Index Year With Active Cancer · 2019	16 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	130 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	15 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	98 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	298 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	168 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	725 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Charlson Comorbidity Index (CCI) Without Active Cancer	1.21 Units on a scale STANDARD_DEVIATION 1.39 • n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1.23 Units on a scale STANDARD_DEVIATION 1.37 • n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1.21 Units on a scale STANDARD_DEVIATION 1.43 • n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1.22 Units on a scale STANDARD_DEVIATION 1.38 • n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1.15 Units on a scale STANDARD_DEVIATION 1.37 • n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1.45 Units on a scale STANDARD_DEVIATION 1.61 • n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1.22 Units on a scale STANDARD_DEVIATION 1.41 • n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Charlson Comorbidity Index (CCI) With Active Cancer	4.84 Units on a scale STANDARD_DEVIATION 2.83 • n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4.74 Units on a scale STANDARD_DEVIATION 2.85 • n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4.77 Units on a scale STANDARD_DEVIATION 2.77 • n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4.69 Units on a scale STANDARD_DEVIATION 2.95 • n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	5.02 Units on a scale STANDARD_DEVIATION 2.99 • n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	5.09 Units on a scale STANDARD_DEVIATION 3.00 • n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4.98 Units on a scale STANDARD_DEVIATION 2.96 • n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
HAS-BLED Score Without Active Cancer	2.19 Units on a scale STANDARD_DEVIATION 1.16 • n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2.31 Units on a scale STANDARD_DEVIATION 1.09 • n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2.24 Units on a scale STANDARD_DEVIATION 1.10 • n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2.24 Units on a scale STANDARD_DEVIATION 1.10 • n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2.16 Units on a scale STANDARD_DEVIATION 1.11 • n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2.26 Units on a scale STANDARD_DEVIATION 1.18 • n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2.20 Units on a scale STANDARD_DEVIATION 1.13 • n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
HAS-BLED Score With Active Cancer	2.45 Units on a scale STANDARD_DEVIATION 1.11 • n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2.41 Units on a scale STANDARD_DEVIATION 1.07 • n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2.46 Units on a scale STANDARD_DEVIATION 1.10 • n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2.47 Units on a scale STANDARD_DEVIATION 1.14 • n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2.38 Units on a scale STANDARD_DEVIATION 1.13 • n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2.23 Units on a scale STANDARD_DEVIATION 1.17 • n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2.35 Units on a scale STANDARD_DEVIATION 1.14 • n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Corticosteroids: Without Active Cancer	5109 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1787 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	797 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	726 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	10415 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2492 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	21326 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Corticosteroids: With Active Cancer	531 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	266 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	121 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	129 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2066 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1403 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4516 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications NSAIDs: Without Active Cancer	8135 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3657 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1492 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1622 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	18695 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4774 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	38375 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications NSAIDs: With Active Cancer	670 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	397 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	172 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	225 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2601 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1704 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	5769 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications ACE inhibitors: Without Active Cancer	4840 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2086 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	867 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1005 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	10036 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3052 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	21886 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications ACE inhibitors: With Active Cancer	513 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	295 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	122 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	160 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1920 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1163 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4173 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Angiotensin II receptor blockers: Without Active Cancer	5083 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2364 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	961 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1108 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	10925 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3283 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	23724 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Angiotensin II receptor blockers: With Active Cancer	397 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	233 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	103 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	130 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1492 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	888 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3243 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Antiplatelets: Without Active Cancer	3958 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1763 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	752 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	868 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	8580 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2773 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	18694 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Antiplatelets: With Active Cancer	229 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	159 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	58 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	84 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	895 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	507 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1932 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Beta-blockers: Without Active Cancer	2124 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	825 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	361 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	432 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4218 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1272 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	9232 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Beta-blockers: With Active Cancer	155 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	72 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	44 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	53 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	547 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	293 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1164 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Calcium-channel blockers: Without Active Cancer	3522 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1680 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	658 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	778 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	7703 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2436 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	16777 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Calcium-channel blockers: With Active Cancer	311 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	181 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	82 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	102 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1161 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	698 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2535 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications SSRI: Without Active Cancer	725 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	404 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	170 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	216 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1913 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	464 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3892 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications SSRI: With Active Cancer	41 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	28 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	17 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	17 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	190 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	98 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	391 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Proton pump inhibitors: Without Active Cancer	2995 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1607 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	693 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	759 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	7550 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1925 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	15529 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Proton pump inhibitors: With Active Cancer	398 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	262 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	112 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	152 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1656 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1057 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3637 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Diuretics: Without Active Cancer	2270 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	796 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	379 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	425 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4066 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1306 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	9242 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Diuretics: With Active Cancer	337 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	183 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	78 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	113 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1379 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	770 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2860 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Thiazides: Without Active Cancer	2168 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	842 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	359 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	385 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4253 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1133 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	9140 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Thiazides: With Active Cancer	139 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	65 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	22 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	28 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	403 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	245 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	902 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Vasodilators: Without Active Cancer	2532 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1109 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	466 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	505 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	5595 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1593 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	11800 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Vasodilators: With Active Cancer	128 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	86 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	42 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	45 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	467 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	274 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1042 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Estrogens: Without Active Cancer	182 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	96 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	21 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	43 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	466 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	108 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	916 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Estrogens: With Active Cancer	23 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	12 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	5 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	62 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	37 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	142 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Cyclooxygenase-2 inhibitors: Without Active Cancer	1184 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1044 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	360 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	389 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3956 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	929 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	7862 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Cyclooxygenase-2 inhibitors: With Active Cancer	72 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	70 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	29 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	26 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	332 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	216 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	745 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Triazole antifungal agents: Without Active Cancer	774 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	329 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	130 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	129 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1675 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	383 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3420 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Previous use of Medications Triazole antifungal agents: With Active Cancer	55 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	33 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	13 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	20 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	219 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	120 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	460 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Antiphospholipid syndrome: Without Active Cancer	280 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	85 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	42 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	41 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	589 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	76 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1113 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Antiphospholipid syndrome: With Active Cancer	8 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	8 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	91 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	87 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	199 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Asthma: Without Active Cancer	1184 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	424 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	203 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	236 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2351 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	546 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4944 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Asthma: With Active Cancer	92 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	44 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	26 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	23 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	271 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	152 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	608 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities History of cancer: Without Active Cancer	897 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	524 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	196 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	253 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2432 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	904 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	5206 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities History of cancer: With Active Cancer	—	—	—	—	—	—	0 Participants Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities COPD: Without Active Cancer	1766 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	707 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	332 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	370 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3765 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1010 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	7950 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities COPD: With Active Cancer	179 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	81 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	46 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	50 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	706 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	390 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1452 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Chronic kidney disease: Without Active Cancer	312 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	87 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	32 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	45 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	294 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	215 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	985 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Chronic kidney disease: With Active Cancer	32 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	14 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	5 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	6 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	60 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	40 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	157 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Chronic liver disease: Without Active Cancer	800 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	392 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	146 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	145 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1723 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	537 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3743 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Chronic liver disease: With Active Cancer	91 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	68 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	28 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	37 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	456 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	339 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1019 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Diabetes mellitus: Without Active Cancer	1818 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	866 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	326 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	335 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3826 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1454 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	8625 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Diabetes mellitus: With Active Cancer	161 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	92 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	51 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	65 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	695 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	455 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1519 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Fracture: Without Active Cancer	1137 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	511 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	258 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	273 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2601 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	802 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	5582 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Fracture: With Active Cancer	43 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	37 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	15 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	15 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	202 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	118 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	430 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Heart failure: Without Active Cancer	538 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	207 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	99 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	123 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	906 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	273 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2146 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Heart failure: With Active Cancer	29 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	8 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	6 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	67 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	35 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	146 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Hyperlipidemia: Without Active Cancer	1735 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1093 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	363 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	432 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4452 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1225 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	9300 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Hyperlipidemia: With Active Cancer	130 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	99 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	44 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	68 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	584 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	377 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1302 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Hypertension: Without Active Cancer	4525 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2086 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	821 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	920 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	9679 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2916 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	20947 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Hypertension: With Active Cancer	335 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	205 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	79 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	97 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1284 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	772 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	2772 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Ischemic heart disease: Without Active Cancer	235 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	91 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	34 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	60 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	463 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	201 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1084 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Ischemic heart disease: With Active Cancer	15 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	10 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	3 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	8 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	60 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	25 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	121 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Myocardial infarction: Without Active Cancer	53 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	25 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	10 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	6 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	88 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	89 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	271 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Myocardial infarction: With Active Cancer	4 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	8 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	8 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	24 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Stroke: Without Active Cancer	956 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	394 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	182 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	220 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1987 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	796 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4535 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Stroke: With Active Cancer	56 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	27 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	17 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	15 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	172 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	96 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	383 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Trauma: Without Active Cancer	43 Participants n=10390 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	10 Participants n=4543 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4 Participants n=1894 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4 Participants n=2078 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	67 Participants n=23049 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	20 Participants n=6550 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	148 Participants n=48504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.
Number of Participants With Comorbidities Trauma: With Active Cancer	1 Participants n=818 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	1 Participants n=504 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=209 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	0 Participants n=264 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	8 Participants n=3227 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	4 Participants n=2233 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.	14 Participants n=7255 Participants • Baseline characteristic is reported in separate rows for participants with active cancer and without active cancer.

PRIMARY outcome

Timeframe: From index date up to treatment interruption, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Population: Analysis population included all eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as one entity, while individual NOAC results discriminated between each NOAC, therefore total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. Here, "Number Analyzed" signifies participants evaluable for specified rows.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=11208 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=35768 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=5047 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=2103 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=2342 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=26276 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=8783 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants With Interruption in Index Anticoagulant Treatment Without Active Cancer	3429 Participants	8169 Participants	965 Participants	492 Participants	439 Participants	5973 Participants	1226 Participants
Number of Participants With Interruption in Index Anticoagulant Treatment With Active Cancer	172 Participants	961 Participants	115 Participants	51 Participants	38 Participants	728 Participants	401 Participants

PRIMARY outcome

Timeframe: From index date up to treatment interruption, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Population: All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. "Overall Number of Participants Analyzed": participants evaluable for this outcome measure with interruption event;"Number Analyzed": participants evaluable for specified rows.

Treatment interruption was defined as when a participant had a gap with no new treatment within 30 days of the estimated end of supply of index treatment, but subsequently restarted the index treatment after this period of 30 days. The time to treatment interruption was defined as the period from the index date to the date of treatment interruption. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=3601 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=9130 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=1080 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=543 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=477 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=6701 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=1627 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Time to Treatment Interruption Without Active Cancer	163 Days Interval 50.0 to 343.0	129 Days Interval 37.0 to 189.0	86 Days Interval 16.0 to 181.0	137 Days Interval 56.0 to 188.0	130 Days Interval 42.0 to 189.0	128 Days Interval 38.0 to 188.0	3 Days Interval 1.0 to 10.0
Time to Treatment Interruption With Active Cancer	129 Days Interval 50.0 to 270.0	137 Days Interval 51.0 to 188.0	123 Days Interval 59.0 to 186.0	119 Days Interval 58.0 to 188.0	159 Days Interval 30.0 to 199.0	134 Days Interval 49.0 to 187.0	61 Days Interval 7.0 to 160.0

PRIMARY outcome

Timeframe: From index date up to treatment switch, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Treatment switching was defined as a prescription of another anticoagulant therapy that was started after the treatment initiation of the index anticoagulant treatment and within 30 days after the estimated end of supply of the index anticoagulant drug (exposure to the new anticoagulant treatment must last for at least 30 days to be considered as a treatment switch). The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=11208 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=35768 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=5047 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=2103 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=2342 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=26276 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=8783 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants Who Switched to Another Anticoagulant Therapy Without Active Cancer	1541 Participants	1273 Participants	319 Participants	276 Participants	204 Participants	1777 Participants	535 Participants
Number of Participants Who Switched to Another Anticoagulant Therapy With Active Cancer	144 Participants	173 Participants	33 Participants	30 Participants	26 Participants	208 Participants	208 Participants

PRIMARY outcome

Timeframe: From index date up to treatment switch, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Population: All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. "Overall Number of Participants Analyzed": participants evaluable for this outcome measure with switch event; "Number Analyzed": participants evaluable for specified rows.

Treatment switching was defined as a prescription of another anticoagulant therapy that was started after the treatment initiation of the index anticoagulant treatment and within 30 days after the estimated end of supply of the index anticoagulant drug (exposure to the new anticoagulant treatment must last for at least 30 days to be considered as a treatment switch). The time to treatment switch was defined as the period from the index date to the date of treatment switch. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=1685 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=1446 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=352 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=306 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=230 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=1985 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=743 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Time to Treatment Switch Without Active Cancer	57 Days Interval 21.0 to 182.0	179 Days Interval 53.0 to 199.0	66 Days Interval 24.0 to 181.0	105 Days Interval 32.0 to 189.0	87 Days Interval 25.0 to 189.0	99 Days Interval 23.0 to 189.0	27 Days Interval 19.0 to 39.0
Time to Treatment Switch With Active Cancer	36 Days Interval 13.0 to 99.0	76 Days Interval 20.0 to 172.0	44 Days Interval 14.0 to 109.0	60 Days Interval 30.0 to 174.0	98 Days Interval 28.0 to 150.0	53 Days Interval 21.0 to 149.0	49 Days Interval 27.0 to 102.0

PRIMARY outcome

Timeframe: From index date up to treatment discontinuation, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Treatment discontinuation (complete discontinuation; no reinitiation) was defined as when a participant who ended their first continuous treatment episode with the index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=11208 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=35768 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=5047 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=2103 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=2342 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=26276 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=8783 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants Who Completely Discontinued Index Anticoagulant Treatment With Active Cancer	444 Participants	2570 Participants	279 Participants	115 Participants	147 Participants	1968 Participants	1449 Participants
Number of Participants Who Completely Discontinued Index Anticoagulant Treatment Without Active Cancer	4707 Participants	19826 Participants	2828 Participants	1028 Participants	1164 Participants	14170 Participants	4534 Participants

PRIMARY outcome

Timeframe: From index date up to treatment discontinuation, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Population: All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC,hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. "Overall Number of Participants Analyzed":participants evaluable for this outcome measure with discontinuation event;"Number Analyzed":participants evaluable for specified rows.

Treatment discontinuation (complete discontinuation; no reinitiation) was defined as when a participant who ended their first continuous treatment episode with the index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. The time to treatment discontinuation was defined as the period from the index date to the date of treatment discontinuation. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=5151 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=22396 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=3107 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=1143 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=1311 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=16138 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=5983 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Time to Treatment Discontinuation With Active Cancer	75 Days Interval 26.0 to 184.0	101 Days Interval 35.0 to 180.0	99 Days Interval 35.0 to 179.0	118 Days Interval 46.0 to 178.0	112 Days Interval 44.0 to 187.0	97 Days Interval 31.0 to 179.0	25 Days Interval 4.0 to 95.0
Time to Treatment Discontinuation Without Active Cancer	129 Days Interval 31.0 to 244.0	119 Days Interval 34.0 to 185.0	84 Days Interval 16.0 to 176.0	134 Days Interval 60.0 to 186.0	154 Days Interval 58.0 to 190.0	119 Days Interval 31.0 to 185.0	2 Days Interval 1.0 to 7.0

PRIMARY outcome

Timeframe: From index date up to the earliest of treatment interruption, switch, or discontinuation; during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Overall anticoagulant treatment duration was defined as the time period from the index date to the earliest of treatment interruption, switch, or discontinuation. Treatment interruption: when a participant had a gap with no new treatment within 30 days of estimated end of supply of index treatment, but subsequently restarted index treatment after this period of 30 days. Treatment switching: a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Treatment discontinuation: when a participant who ended their first continuous treatment episode with index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. The index date was defined as the date of first prescription for anticoagulants within 30 days after the index VTE event.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=11208 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=35768 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=5047 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=2103 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=2342 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=26276 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=8783 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Overall Index Anticoagulant Treatment Duration Without Active Cancer	139 Days Interval 36.0 to 317.0	140 Days Interval 39.0 to 191.0	96 Days Interval 21.0 to 185.0	137 Days Interval 54.0 to 188.0	164 Days Interval 58.0 to 202.0	128 Days Interval 34.0 to 189.0	3 Days Interval 1.0 to 12.0
Overall Index Anticoagulant Treatment Duration With Active Cancer	80 Days Interval 25.0 to 192.0	111 Days Interval 39.0 to 184.0	104 Days Interval 42.0 to 182.0	105 Days Interval 44.0 to 178.0	123 Days Interval 41.0 to 198.0	102 Days Interval 34.0 to 182.0	34 Days Interval 7.0 to 115.0

PRIMARY outcome

Timeframe: Within 3 months of index date, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Participants were considered to be persistent on index anticoagulant treatment if a participant had evidence of a repeat prescription within 30 days of the end of their prescription and does not experience any of the events that included treatment interruption (participant had a gap with no new treatment within 30 days of estimated end of supply of index treatment, but subsequently restarted index treatment after 30 days), switch (prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug), or discontinuation (participant ended their first continuous treatment episode with index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time). Index date: date of first prescription for anticoagulants within 30 days after the index VTE event.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=11208 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=35768 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=5047 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=2103 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=2342 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=26276 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=8783 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months Without Active Cancer	6313 Participants	19848 Participants	2390 Participants	1225 Participants	1395 Participants	14037 Participants	222 Participants
Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 3 Months With Active Cancer	388 Participants	2405 Participants	290 Participants	120 Participants	148 Participants	1770 Participants	673 Participants

PRIMARY outcome

Timeframe: Within 6 months of index date, during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=11208 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=35768 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=5047 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=2103 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=2342 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=26276 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=8783 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months Without Active Cancer	4393 Participants	10557 Participants	1213 Participants	606 Participants	817 Participants	7209 Participants	75 Participants
Number of Participants Who Were Persistent on Index Anticoagulant Treatment for 6 Months With Active Cancer	217 Participants	1089 Participants	125 Participants	46 Participants	91 Participants	773 Participants	221 Participants

PRIMARY outcome

Timeframe: Within 30 days before treatment interruption during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment interruption. Treatment interruption was defined as when a participant had a gap with no new treatment within 30 days of the estimated end of supply of index treatment, but subsequently restarted the index treatment after this period of 30 days. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=3601 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=9130 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=1080 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=543 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=477 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=6701 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=1627 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Major Bleeding: Without Active Cancer	27 Participants	53 Participants	5 Participants	2 Participants	2 Participants	42 Participants	4 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Complications of VTE: Without Active Cancer	6 Participants	13 Participants	0 Participants	3 Participants	0 Participants	10 Participants	5 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Major Surgery: Without Active Cancer	92 Participants	566 Participants	126 Participants	9 Participants	17 Participants	407 Participants	171 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Cancer-related Event: Without Active Cancer	62 Participants	126 Participants	14 Participants	5 Participants	4 Participants	99 Participants	100 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Kidney Function Changes: Without Active Cancer	45 Participants	87 Participants	10 Participants	8 Participants	7 Participants	55 Participants	44 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Complications of VTE: With Active Cancer	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Thromboembolism: With Active Cancer	12 Participants	21 Participants	3 Participants	1 Participants	0 Participants	17 Participants	9 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Major Surgery: With Active Cancer	15 Participants	33 Participants	1 Participants	2 Participants	1 Participants	27 Participants	55 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Kidney Function Changes: With Active Cancer	1 Participants	8 Participants	1 Participants	0 Participants	0 Participants	7 Participants	10 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Liver Function Change: With Active Cancer	2 Participants	9 Participants	3 Participants	1 Participants	0 Participants	5 Participants	9 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Thromboembolism: Without Active Cancer	158 Participants	328 Participants	50 Participants	19 Participants	18 Participants	233 Participants	209 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Liver Function Change: Without Active Cancer	79 Participants	158 Participants	12 Participants	7 Participants	6 Participants	129 Participants	72 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Interruption Major Bleeding: With Active Cancer	1 Participants	8 Participants	3 Participants	0 Participants	0 Participants	4 Participants	2 Participants

PRIMARY outcome

Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Population: All eligible participants. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC, hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. "Overall Number of Participants Analyzed": participants evaluable for this outcome measure with switch event. "Number Analyzed (n)": participants evaluable for specified rows. n =0 as switch in the same treatment arm not feasible.

Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event "major bleeding" are reported.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=1685 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=1446 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=352 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=306 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=230 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=1985 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=743 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to PAC: Without Active Cancer	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	—
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to Rivaroxaban: Without Active Cancer	12 Participants	—	0 Participants	1 Participants	0 Participants	—	7 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to Warfarin: With Active Cancer	—	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to NOAC: With Active Cancer	0 Participants	—	—	—	—	—	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to PAC: With Active Cancer	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants	—
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to Edoxaban: With Active Cancer	0 Participants	—	0 Participants	0 Participants	—	2 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to Dabigatran: With Active Cancer	0 Participants	—	0 Participants	—	0 Participants	0 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to Rivaroxaban: With Active Cancer	0 Participants	—	0 Participants	0 Participants	0 Participants	—	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to Warfarin: Without Active Cancer	—	5 Participants	0 Participants	0 Participants	1 Participants	4 Participants	5 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to NOAC: Without Active Cancer	17 Participants	—	—	—	—	—	11 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to Apixaban: Without Active Cancer	2 Participants	—	—	1 Participants	1 Participants	9 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to Dabigatran: Without Active Cancer	3 Participants	—	0 Participants	—	0 Participants	2 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to Edoxaban: Without Active Cancer	0 Participants	—	3 Participants	0 Participants	—	3 Participants	2 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Bleeding Switched to Apixaban: With Active Cancer	0 Participants	—	—	0 Participants	0 Participants	1 Participants	0 Participants

PRIMARY outcome

Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event "complications of VTE" are reported.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=1685 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=1446 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=352 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=306 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=230 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=1985 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=743 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to Warfarin: Without Active Cancer	—	12 Participants	0 Participants	0 Participants	0 Participants	11 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to Dabigatran: Without Active Cancer	1 Participants	—	0 Participants	—	0 Participants	0 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to PAC: With Active Cancer	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to Apixaban: With Active Cancer	0 Participants	—	—	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to NOAC: Without Active Cancer	2 Participants	—	—	—	—	—	2 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to PAC: Without Active Cancer	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to Apixaban: Without Active Cancer	0 Participants	—	—	0 Participants	0 Participants	1 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to Edoxaban: Without Active Cancer	0 Participants	—	1 Participants	0 Participants	—	2 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to Rivaroxaban: Without Active Cancer	0 Participants	—	0 Participants	0 Participants	0 Participants	—	2 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to Warfarin: With Active Cancer	—	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to NOAC: With Active Cancer	0 Participants	—	—	—	—	—	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to Dabigatran: With Active Cancer	0 Participants	—	0 Participants	—	0 Participants	0 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to Edoxaban: With Active Cancer	0 Participants	—	0 Participants	0 Participants	—	0 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Complications of VTE Switched to Rivaroxaban: With Active Cancer	0 Participants	—	0 Participants	0 Participants	0 Participants	—	0 Participants

PRIMARY outcome

Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event "thromboembolism" are reported.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=1685 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=1446 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=352 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=306 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=230 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=1985 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=743 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to Warfarin: Without Active Cancer	—	59 Participants	6 Participants	3 Participants	2 Participants	48 Participants	12 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to Rivaroxaban: Without Active Cancer	85 Participants	—	14 Participants	6 Participants	9 Participants	—	36 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to Apixaban: With Active Cancer	1 Participants	—	—	0 Participants	0 Participants	4 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to Dabigatran: With Active Cancer	3 Participants	—	0 Participants	—	0 Participants	1 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to Edoxaban: With Active Cancer	0 Participants	—	1 Participants	0 Participants	—	1 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to Rivaroxaban: With Active Cancer	8 Participants	—	0 Participants	3 Participants	0 Participants	—	5 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to NOAC: Without Active Cancer	108 Participants	—	—	—	—	—	51 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to PAC: Without Active Cancer	5 Participants	15 Participants	1 Participants	0 Participants	1 Participants	13 Participants	—
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to Apixaban: Without Active Cancer	8 Participants	—	—	1 Participants	4 Participants	30 Participants	6 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to Dabigatran: Without Active Cancer	9 Participants	—	1 Participants	—	3 Participants	15 Participants	3 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to Edoxaban: Without Active Cancer	7 Participants	—	9 Participants	1 Participants	—	25 Participants	6 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to Warfarin: With Active Cancer	—	9 Participants	1 Participants	0 Participants	0 Participants	8 Participants	4 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to NOAC: With Active Cancer	12 Participants	—	—	—	—	—	8 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Thromboembolism Switched to PAC: With Active Cancer	7 Participants	9 Participants	0 Participants	0 Participants	1 Participants	8 Participants	—

PRIMARY outcome

Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event "major surgery" are reported.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=1685 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=1446 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=352 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=306 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=230 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=1985 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=743 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to Warfarin: Without Active Cancer	—	13 Participants	0 Participants	2 Participants	1 Participants	10 Participants	14 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to PAC: Without Active Cancer	3 Participants	6 Participants	0 Participants	1 Participants	0 Participants	5 Participants	—
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to Warfarin: With Active Cancer	—	2 Participants	0 Participants	0 Participants	0 Participants	2 Participants	2 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to NOAC: With Active Cancer	3 Participants	—	—	—	—	—	18 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to PAC: With Active Cancer	1 Participants	3 Participants	1 Participants	0 Participants	0 Participants	2 Participants	—
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to Apixaban: With Active Cancer	0 Participants	—	—	0 Participants	0 Participants	1 Participants	2 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to NOAC: Without Active Cancer	26 Participants	—	—	—	—	—	65 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to Apixaban: Without Active Cancer	1 Participants	—	—	1 Participants	2 Participants	11 Participants	11 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to Dabigatran: Without Active Cancer	4 Participants	—	0 Participants	—	0 Participants	5 Participants	5 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to Edoxaban: Without Active Cancer	3 Participants	—	4 Participants	2 Participants	—	8 Participants	10 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to Rivaroxaban: Without Active Cancer	18 Participants	—	2 Participants	1 Participants	1 Participants	—	36 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to Dabigatran: With Active Cancer	0 Participants	—	0 Participants	—	0 Participants	1 Participants	5 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to Edoxaban: With Active Cancer	1 Participants	—	0 Participants	0 Participants	—	3 Participants	2 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Major Surgery Switched to Rivaroxaban: With Active Cancer	2 Participants	—	0 Participants	1 Participants	1 Participants	—	9 Participants

PRIMARY outcome

Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event "cancer-related event" are reported among participants without active cancer. Data not collected and reported for participants with active because all participants already had cancer.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=1541 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=1273 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=319 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=276 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=204 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=1777 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=535 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event Switched to NOAC: Without Active Cancer	26 Participants	—	—	—	—	—	57 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event Switched to Apixaban: Without Active Cancer	5 Participants	—	—	1 Participants	0 Participants	6 Participants	11 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event Switched to Edoxaban: Without Active Cancer	1 Participants	—	2 Participants	0 Participants	—	3 Participants	6 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event Switched to Dabigatran: Without Active Cancer	1 Participants	—	1 Participants	—	0 Participants	3 Participants	5 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event Switched to Rivaroxaban: Without Active Cancer	19 Participants	—	0 Participants	3 Participants	5 Participants	—	35 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event Switched to Warfarin: Without Active Cancer	—	13 Participants	1 Participants	1 Participants	0 Participants	11 Participants	6 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Cancer-related Event Switched to PAC: Without Active Cancer	24 Participants	32 Participants	2 Participants	2 Participants	1 Participants	27 Participants	—

PRIMARY outcome

Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event "kidney function change" are reported.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=1685 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=1446 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=352 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=306 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=230 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=1985 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=743 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to Apixaban: Without Active Cancer	3 Participants	—	—	0 Participants	1 Participants	10 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to PAC: With Active Cancer	0 Participants	4 Participants	0 Participants	1 Participants	0 Participants	3 Participants	—
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to Warfarin: Without Active Cancer	—	13 Participants	1 Participants	0 Participants	0 Participants	12 Participants	5 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to NOAC: Without Active Cancer	22 Participants	—	—	—	—	—	4 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to PAC: Without Active Cancer	6 Participants	5 Participants	3 Participants	0 Participants	0 Participants	2 Participants	—
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to Dabigatran: Without Active Cancer	1 Participants	—	1 Participants	—	0 Participants	1 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to Edoxaban: Without Active Cancer	1 Participants	—	0 Participants	0 Participants	—	1 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to Rivaroxaban: Without Active Cancer	17 Participants	—	2 Participants	2 Participants	1 Participants	—	2 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to Warfarin: With Active Cancer	—	2 Participants	0 Participants	0 Participants	0 Participants	2 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to NOAC: With Active Cancer	2 Participants	—	—	—	—	—	2 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to Apixaban: With Active Cancer	1 Participants	—	—	0 Participants	0 Participants	0 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to Dabigatran: With Active Cancer	0 Participants	—	0 Participants	—	0 Participants	0 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to Edoxaban: With Active Cancer	0 Participants	—	0 Participants	0 Participants	—	1 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Kidney Function Change Switched to Rivaroxaban: With Active Cancer	1 Participants	—	0 Participants	0 Participants	0 Participants	—	0 Participants

PRIMARY outcome

Timeframe: Within 30 days before treatment switch during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment switch. Treatment switching was defined as a prescription of another anticoagulant therapy that was started after treatment initiation of index anticoagulant treatment and within 30 days after estimated end of supply of index anticoagulant drug. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event. In this outcome measure, results for event "liver function change" are reported.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=1685 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=1446 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=352 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=306 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=230 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=1985 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=743 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to Warfarin: Without Active Cancer	—	36 Participants	3 Participants	4 Participants	1 Participants	28 Participants	10 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to Warfarin: With Active Cancer	—	3 Participants	1 Participants	0 Participants	0 Participants	2 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to NOAC: With Active Cancer	1 Participants	—	—	—	—	—	7 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to Apixaban: With Active Cancer	0 Participants	—	—	0 Participants	0 Participants	2 Participants	1 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to Dabigatran: With Active Cancer	0 Participants	—	0 Participants	—	0 Participants	0 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to NOAC: Without Active Cancer	63 Participants	—	—	—	—	—	29 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to PAC: Without Active Cancer	7 Participants	11 Participants	0 Participants	1 Participants	0 Participants	10 Participants	—
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to Apixaban: Without Active Cancer	3 Participants	—	—	1 Participants	1 Participants	13 Participants	5 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to Dabigatran: Without Active Cancer	6 Participants	—	0 Participants	—	2 Participants	4 Participants	4 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to Edoxaban: Without Active Cancer	3 Participants	—	2 Participants	1 Participants	—	20 Participants	5 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to Rivaroxaban: Without Active Cancer	51 Participants	—	6 Participants	2 Participants	6 Participants	—	16 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to PAC: With Active Cancer	3 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to Edoxaban: With Active Cancer	1 Participants	—	0 Participants	0 Participants	—	1 Participants	0 Participants
Number of Participants With Clinical Events Preceding Switch From Index Anticoagulant Treatment: Liver Function Change Switched to Rivaroxaban: With Active Cancer	0 Participants	—	0 Participants	0 Participants	1 Participants	—	6 Participants

PRIMARY outcome

Timeframe: Within 30 days before treatment discontinuation during observation period of maximum up to 88 months (retrospective data was retrieved and observed during 1 month of this study)

Population: All eligible participants whose medical records were retrieved and observed in this study. 'NOAC-based therapy' arm considered all NOACs as 1 entity, while individual NOAC results discriminated between each NOAC,hence total number of participants with outcome in NOAC-based therapy is not equal to sum of individual NOACs. "Overall Number of Participants Analyzed":participants evaluable for this outcome measure with discontinuation event;"Number Analyzed":participants evaluable for specified rows.

Clinical event preceding first treatment change was defined as occurrence of any event (major bleeding, complications of VTE, thromboembolism, major surgeries, cancer-related event, kidney function change, liver function change) within 30 days before treatment discontinuation. Treatment discontinuation (complete discontinuation; no reinitiation) was defined as when a participant who ended their first continuous treatment episode with the index anticoagulant treatment without switching, and subsequently have no further prescriptions for that respective anticoagulant treatment during all available follow-up time. Index date was defined as date of first prescription for anticoagulants within 30 days after index VTE event.

Outcome measures

Outcome measures
Measure	Warfarin-Based Therapy n=5151 Participants Participants diagnosed with VTE, initiated warfarin-based therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy n=22396 Participants Participants diagnosed with VTE, initiated NOAC-based (apixaban, dabigatran, edoxaban, or rivaroxaban) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Apixaban n=3107 Participants Participants diagnosed with VTE, initiated apixaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Dabigatran n=1143 Participants Participants diagnosed with VTE, initiated dabigatran (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Edoxaban n=1311 Participants Participants diagnosed with VTE, initiated edoxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	NOAC-Based Therapy: Rivaroxaban n=16138 Participants Participants diagnosed with VTE, initiated rivaroxaban (NOAC-based) therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.	PAC Only n=5983 Participants Participants diagnosed with VTE, initiated PAC only therapy in real world practice within 30 days of their VTE diagnosis between 1 March 2012 and 30 June 2019, were included in this cohort.
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Kidney Function Changes: With Active Cancer	14 Participants	64 Participants	7 Participants	1 Participants	5 Participants	51 Participants	48 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Major Bleeding: Without Active Cancer	42 Participants	118 Participants	13 Participants	7 Participants	5 Participants	90 Participants	20 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Complications of VTE: Without Active Cancer	10 Participants	25 Participants	4 Participants	2 Participants	3 Participants	15 Participants	18 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Thromboembolism: With Active Cancer	17 Participants	122 Participants	14 Participants	9 Participants	11 Participants	87 Participants	89 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Thromboembolism: Without Active Cancer	258 Participants	777 Participants	123 Participants	48 Participants	53 Participants	537 Participants	734 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Major Surgery: Without Active Cancer	78 Participants	1691 Participants	508 Participants	18 Participants	25 Participants	1138 Participants	625 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Cancer-related Event: Without Active Cancer	133 Participants	307 Participants	40 Participants	14 Participants	20 Participants	232 Participants	291 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Kidney Function Changes: Without Active Cancer	104 Participants	240 Participants	39 Participants	13 Participants	11 Participants	172 Participants	383 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Liver Function Change: Without Active Cancer	158 Participants	452 Participants	65 Participants	34 Participants	28 Participants	321 Participants	441 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Major Bleeding: With Active Cancer	7 Participants	36 Participants	4 Participants	2 Participants	0 Participants	29 Participants	14 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Complications of VTE: With Active Cancer	1 Participants	2 Participants	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Major Surgery: With Active Cancer	11 Participants	66 Participants	7 Participants	1 Participants	5 Participants	52 Participants	190 Participants
Number of Participants With Clinical Events Preceding Index Anticoagulant Treatment Discontinuation Liver Function Change: With Active Cancer	16 Participants	50 Participants	3 Participants	2 Participants	3 Participants	42 Participants	34 Participants

Adverse Events

Warfarin-Based Therapy

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

NOAC-Based Therapy: Apixaban

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

NOAC-Based Therapy: Dabigatran

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

NOAC-Based Therapy: Edoxaban

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

NOAC-Based Therapy: Rivaroxaban

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

PAC Only

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Pfizer ClinicalTrials.gov Call Center

Pfizer Inc.

Phone: 1-800-718-1021

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Publication restrictions are in place

Restriction type: OTHER